Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CC-98633 · 1 trial · 1 indication
incidence and severity of AEs. An AE is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a subject during the course of a study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the subject's health, including laboratory test values, regardless of etiology. Any worsening (ie, any clinically significant adverse change in the frequency or intensity of a preexisting condition) should be considered an AE.
| Arm | Type | Description |
|---|---|---|
| CC-98633 | EXPERIMENTAL | Subjects will receive CC-98633 following 3 consecutive doses of lymphodepleting chemotherapy (fludarabine and cyclophosphamide). |
| Name | Type | Description |
|---|---|---|
| CC-98633 | BIOLOGICAL | Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) to produce CC-98633. During CC-98633 production, subjects may receive bridging chemotherapy for disease control. Upon successful generation of CC-98633 product, subjects will receive treatment with CC-98633 therapy. Study treatment will include lymphodepleting chemotherapy followed by one dose of CC-98633 administered by intravenous (IV) injection. |
Inclusion Criteria: 1. Age ≥ 18 years. 2. Signed written informed consent prior to any study procedure. 3. Relapsed and/or refractory multiple myeloma (MM). 1. Subjects must have documented progressive disease as per International Myeloma Working Group (IMWG) criteria during or within 12 months...
Top 20 of 25 competitors
CC-98633 is an investigational monoclonal antibody being developed for the treatment of multiple myeloma. It is a BCMA-targeted chimeric antigen receptor (CAR) T cell therapy studied in participants with relapsed and/or refractory multiple myeloma. The drug is currently in Phase 1 clinical development.
CC-98633 targets BCMA, which stands for B-cell maturation antigen. It is a BCMA-targeted chimeric antigen receptor (CAR) T cell therapy designed to recognize and attack cells expressing BCMA, which is commonly found on multiple myeloma cells. This targeting mechanism is central to its investigational use in treating multiple myeloma.
CC-98633 is being developed by cbdMD, Inc., a company traded on the stock market under the ticker symbol YCBD. The company is conducting clinical research on this investigational therapy for multiple myeloma, with the drug currently in Phase 1 development.
CC-98633 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still being studied in clinical trials. The Phase 1 trial for CC-98633 has been completed, and the drug remains under investigation for multiple myeloma.
CC-98633 has one completed clinical trial registered under NCT04394650. This Phase 1 study, titled 'A Study of CC-98633, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Participants With Relapsed and/or Refractory Multiple Myeloma,' enrolled 78 participants in the United States. The trial was uncontrolled and not randomized or double-blinded.
CC-98633 is a BCMA-targeted chimeric antigen receptor (CAR) T cell therapy. The clinical trial NCT04394650 specifically describes CC-98633 as BCMA-targeted CAR T cells, indicating that CC-98633 is a form of CAR T cell therapy directed against BCMA for the treatment of multiple myeloma.